Date: 29 Aug 2013
Alzheimer’s disease is most common in elderly people affected with dementia. We are expecting a large increase in the incidence rate of dementia and Alzheimer’s disease in the world. Therefore, how to prevent or treat dementia and Alzheimer’s disease is an urgent issue for us. Alzheimer’s disease is characterized by amyloid-β protein and tau deposition in the brain. Amyloid-β protein plays a central role in the development of Alzheimer’s disease, but the pathogenesis is not well understood. Here we find evidence that, amyloid-β protein causes one type of post-translational modification, phosphorylation of a protein, named Collapsin response mediator protein 2 (CRMP2), in the brain, and this phosphorylation plays a key role in Alzheimer’s disease model. We propose that CRMP2 is a candidate therapeutic target or biomarker for onset and/or development of Alzheimer’s disease.
This result of research is published at “Neuroscience Research” (29 August 2013 online edition).
Yoshio Goshima, M.D. & Ph.D.
Professor, Department of Molecular Pharmacology & Neurobiology, Graduate School of Medicine,
Yokohama City University